Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Public ClinicalTrials.gov record NCT02542293. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.
Study identification
- NCT ID
- NCT02542293
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 953 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab +Tremelimumab Biological
- Paclitaxel + carboplatin Drug
- Gemcitabine + cisplatin Drug
- Gemcitabine + carboplatin Drug
- Pemetrexed + cisplatin Drug
- Pemetrexed + carboplatin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 3, 2015 (Actual)
- Primary completion
- Sep 21, 2020 (Actual)
- Completion
- Dec 31, 2026 (Estimated)
- Last update posted
- Aug 6, 2026
2015 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anaheim | California | 92801 | — |
| Research Site | San Diego | California | 92123 | — |
| Research Site | Santa Rosa | California | 95403 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Florham Park | New Jersey | 07932 | — |
| Research Site | Albuquerque | New Mexico | 87102 | — |
| Research Site | East Setauket | New York | 11733 | — |
| Research Site | Fresh Meadows | New York | 11366 | — |
| Research Site | Poughkeepsie | New York | 12601 | — |
| Research Site | Stony Brook | New York | 11794 | — |
| Research Site | Canton | Ohio | 44710 | — |
| Research Site | Columbus | Ohio | 43219 | — |
| Research Site | Zanesville | Ohio | 43701 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Houston | Texas | 77090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 195 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02542293, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2026 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02542293 live on ClinicalTrials.gov.